Closed · RFA-HL-19-018 · CFDA 93.233;93.350;93.837;93.838;93.839;93.840 · Discretionary

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $1M
Award range
Closed
Status
July 9, 2020
Close date
2
Expected awards

The verdict

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $1,000,000 across 2 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $1M
award range
Closed
application status
2
expected awards
93.233;93.350;93.837;93.838;93.839;93.840
CFDA program

Archived opportunity record

NHLBI SBIR Phase IIB Small Market Awards to A… is closed (last close July 9, 2020). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed July 9, 2020

Posted May 16 Closes Jul 9

Est. Total Funding

$700,000

Expected Awards

2

Instrument

Grant

Description

The purpose of the NHLBI SBIR Phase IIB Small Market Award is to provide support to Phase II SBIR or STTR awardees that are developing NHLBI mission-related products that address a rare disease or young pediatric populations. The goal of this FOA is for these products to be further validated so that development can continue with private funding after NHLBI support ends. Applicants must submit a Commercialization Plan that includes details on any independent third-party funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will be equal to or greater than one-third of the NHLBI funds being requested throughout the project period. Projects proposed in response to this FOA must require eventual Federal regulatory approval/clearance, and may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.

Small-business / for-profit corridor · RFA-HL-19-018

NHLBI SBIR Phase IIB Small Market Awards to A… prints a for-profit / small-business applicant door (Small businesses). Treat the listing as business-facing unless the full Grants.gov announcement narrows it further. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Health (HL). 789 other National Institutes of Health listings share this eligibility-code string (6% of 12,420).

Code 23
Small businesses

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

More from National Institutes of Health

Closed Closed October 2, 2026

Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)

View →
Closed Closed October 2, 2026

Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)

View →
Closed Closed October 9, 2026

Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)

View →
Closed Closed October 19, 2026

PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)

View →
Closed Closed October 19, 2026

Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)

View →

What to do next

NHLBI SBIR Phase IIB Small Market Awards to A… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.233;93.350;93.837;93.838;93.839;93.840 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Read our methodology - how this data is sourced, computed, and verified.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants